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Background: Osteosarcoma is one of the most common bone cancers in children. Most patients with metastatic
osteosarcoma die of pulmonary disease and limited curative therapeutic options exist for such patients. We have
previously shown that PD-1 limits the efficacy of CTL to mediate immune control of metastatic osteosarcoma in the
K7M2 mouse model of pulmonary metastatic disease and that blockade of PD-1/PD-L1 interactions can partially
improve survival outcomes by enhancing the function of osteosarcoma-specific CTL. However, PD-1/PD-L1
blockade-treated mice eventually succumb to disease due to selection of PD-L1 mAb-resistant tumor cells. We
investigated the mechanism of tumor cell resistance after blockade, and additional combinational therapies to
combat resistance.
Methods: We used an implantable model of metastatic osteosarcoma, and evaluated survival using a Log-rank
test. Cellular analysis of the tumor was done post-mortem with flow cytometry staining, and evaluated using a
T-test to compare treatment groups.
Results: We show here that T cells infiltrating PD-L1 antibody-resistant tumors upregulate additional inhibitory
receptors, notably CTLA-4, which impair their ability to mediate tumor rejection. Based on these results we have
tested combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade in the K7M2 mouse model
of metastatic osteosarcoma and show that this results in complete control of tumors in a majority of mice as
well as immunity to further tumor inoculation.
Conclusions: Thus, combinational immunotherapy approaches to block additional inhibitory pathways in
patients with metastatic osteosarcoma may provide new strategies to enhance tumor clearance and resistance
to disease.Background
The effectiveness of conventional therapies for meta-
static osteosarcoma has remained unchanged over the
last thirty years, with a dismal five-year survival rate of
less than 20% [1-5]. We have recently shown that meta-
static osteosarcoma tumors, but not primary tumors, be-
come resistant to CD8 T cell-mediated control due to* Correspondence: Joseph.Blattman@asu.edu
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unless otherwise stated.upregulation of inhibitory receptors that limit T cell
function [6]. Specifically, in the K7M2 mouse model of
metastatic osteosarcoma, expression of programmed
death receptor-1 (PD-1) and interaction with its ligand
PD-L1 on tumor cells, tolerizes tumor-reactive T cells
inhibiting their cytokine production and cytotoxic func-
tion towards the tumor. Moreover, both our lab and
others have shown that PD-L1 is expressed on human
metastatic osteosarcoma tissue, while CTL infiltrating
human metastatic osteosarcomas are positive for PD-1
[7]. Therefore, immunotherapy, specifically the use of
antibody blockade of such inhibitory proteins, may be an
effective option for treating metastatic osteosarcoma byThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lussier et al. Journal for ImmunoTherapy of Cancer  (2015) 3:21 Page 2 of 11re-invigorating tumor-reactive T cells that can mediate
tumor eradication. In support of this idea, our previous
data shows that α-PD-L1 antibody blockade partially im-
proves T cell function in vitro and in vivo and results in
longer host survival with fewer pulmonary metastases
during disease progression [6]. Unfortunately, metastatic
osteosarcoma tumor-bearing mice treated with α-PD-L1
mAb ultimately succumb to pulmonary disease, with
larger overall metastases that become resistant to PD-L1
antibody therapy. Therefore, combinational immuno-
therapy, by blockade of alternative inhibitory receptor
pathways on T cells or accessory regulatory cells may
lead to more efficient restoration of T cell function and
improve control of metastatic osteosarcoma tumors.
In other experimental and clinical systems, combin-
ational immunotherapies have shown synergistic effects
on the ability of T cells to mediate clearance of tumors,
and in some cases have led to complete control of tumor
growth. Curran et al. combined α-CTLA-4 and α-PD-L1
mAb treatment of an implantable model of B16 melan-
oma and observed more than a 2-fold increase in tumor
rejection compared to α-CTLA-4 mAb alone treated
groups [8]. Combinational immunotherapy using anti-
bodies to CTLA-4, PD-1/PD-L1, with small molecule
inhibitors of indolamine deoxygenase (IDO), have also
been shown to lead to improved tumor control and in-
creased IL-2 production by tumor infiltrating lympho-
cytes (TILs) in an implantable melanoma setting [8,9].
In humans, ipilimumab (α-CTLA-4) and nivolumab (α-
PD-1) mAb combinational blockade has shown promise
in clinical trials against advanced melanoma with 40-50%
of patients achieving objective responses and a reduction
in tumor burden [10]. However, an extremely small study,
looking at 4 synovial sarcoma patients treated with varying
doses of ipilimumab showed no responses [11]. However
disease was very advanced, and these blockade inhibitors
may be best for treating patients with early metastatic
disease, as cells that newly escape into the periphery
may co-opt the use of inhibitory receptors to suppress
T cell mediated killing of malignant cells [12]. These
immune checkpoint blockade strategies also appear to
enhance clearance of tumors when used in combination
with chemotherapy, including during treatment of pan-
creatic cancer in murine models [13].
In our current study, we focus on the mechanism of
resistance of K7M2 metastatic osteosarcoma cells after
α-PD-L1 blockade. Attempting to understand the mech-
anism of resistance leads us to more beneficial combin-
ational approaches against metastatic osteosarcoma.
We will investigate if any combinational approaches
overcome mechanism of resistance, and provide either
significant decreases in tumor growth or complete pro-
tection. Evidence from our model will provide the
necessary pre-clinical data to support testing of suchstrategies in clinical trials of patients with metastatic
osteosarcoma.
Results
Longer duration PD-L1 mAb treatment provides no
additional survival benefit to mice with metastatic
osteosarcoma
Due to escape following PD-L1 mAb treatment, we
wanted to test if PD-L1 mAb treated metastatic osteo-
sarcoma is evading immune mediated killing, or if prolif-
eration rate is outpacing immune mediated killing. To
evaluate if longer α-PD-L1 mAb treatment could further
improve T cell control of metastatic osteosarcoma dis-
ease, we doubled the dose and duration of α-PD-L1
mAb therapy. We observed no significant difference in
the survival of metastatic osteosarcoma implanted mice
when treated for 30 days vs 15 days; mice receiving α-
PD-L1 mAb therapy perished from pulmonary metasta-
ses with a median survival of 68 days in both groups
(Figure 1A). Therefore, we reasoned that metastatic
osteosarcoma cells in these mice are becoming resistant
to α-PD-L1 mAb therapy, and that this may be due, at
least in part, to suppression of T cell responses by signal-
ing via alternative immune inhibitory receptor pathways.
Metastatic osteosarcoma treated with α-PD-L1 downregulate
PD-L1 expression, but increase CD80/CD86 expression
To determine if T cell responses to osteosarcoma metas-
tatses in α-PD-L1 mAb treated mice may have become
tolerized through engagement of other inhibitory li-
gands, we evaluated expression of PD-L1, CD80, and
CD86 on metastatic osteosarcoma cells, in both mock
treated and α-PD-L1 mAb treated mice. PD-L1 expres-
sion on metastatic osteosarcoma was significantly de-
creased after α-PD-L1 mAb treatment suggesting that
these cells are no longer co-opting the use of PD-1 to
suppress T cell function (Figure 1B). Moreover, CD80
and CD86 expression on metastatic osteosarcoma was
significantly increased after α-PD-L1 mAb treatment
suggesting that tumor cells may be directly or indirectly
using this pathway to suppress CTL-mediated killing
(Figure 1B).
Metastatic osteosarcoma reactive T cells from α-PD-L1
mAb treated mice decrease PD-1 but increase CTLA-4
expression
In order to determine if T cell responses to osteosar-
coma metastases in α-PD-L1 mAb treated mice may
have become tolerized through engagement of other
inhibitory ligands, we evaluated expression of PD-1,
CTLA-4, and LAG3 on tumor reactive T cells, as these
inhibitory proteins have been shown to be critically im-
portant in other tumor tolerance settings [14-18]. PD-1
expression on CD8+ TILs was significantly decreased
Figure 1 Higher dose and longer duration of α-PD-L1 mAb treatment does not improve survival, suggesting resistance to α-PD-L1 mAb treatment.
Mice were injected with K7M2 cells, and treated for either 15 days (n = 10) or 30 days (n = 10) with α-PD-L1 mAb. Survival was not significantly different
between the 15 day and 30 day treatment, p = 0.2942, and all mice succumbed to disease (A). At time of necropsy, PD-L1, CD80, and CD86 expression
was evaluated using Flow Jo. PD-L1 expression was significantly decreased in treated versus untreated mice, p = 0.0026. CD80 expression was
significantly increased in treated versus untreated mice, p < 0.0001. CD86 expression was significantly increased in treated versus untreated
mice, p < 0.0001 (B). At time of necropsy, PD-1+, CTLA-4+, and LAG3+ CD8+ expression was evaluated using Flow Jo. PD-1 + CD8+ expression
was significantly different in treated versus untreated mice, p = 0.0005 (C). CTLA-4 + CD8+ expression was significantly different in treated
versus untreated mice, p = 0.043 (D). LAG3 + CD8+ expression was not significantly different between treated and untreated mice (E).
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cells are no longer co-opting the use of PD-1 to suppress
T cell function (Figure 1C), either through downregula-
tion of expression or via ineffective activation to initially
upregulate this receptor. Conversely, tumor infiltrating
CD8 T cells had higher levels of CTLA-4 expression in
α-PD-L1 mAb blockade treated mice, suggesting that
tumor cells may be directly or indirectly using this path-
way to suppress CTL-mediated killing (Figure 1D). No
statistical difference was observed in LAG3 expression
after α-PD-L1 mAb treatment (Figure 1E).
Metastatic osteosarcomas that develop in α-PD-L1 treated
mice are resistant to additional PD-L1 blockade
We also observed lower expression of PD-L1 on K7M2
metastatic osteosarcoma cells from α-PD-L1 mAb-treated
mice compared to tumor cells from mock-treated mice
(Figure 2B). This further suggested that these cells may beusing alternative strategies to evade immune clearance. To
evaluate if down-regulation of PD-L1 by K7M2 metastatic
osteosarcoma cells after α-PD-L1 mAb treatment resulted
in resistance to further α-PD-L1 mAb treatment, versus
indirect inhibition by other tumor resident cells, metasta-
static osteosarcoma cells isolated from α-PD-L1 mAb
treated mice were re-implanted into naïve recipient mice
that were then subsequently treated with α-PD-L1 mAb
or received mock injections (Figure 2A). We reasoned that
if PD-L1 resistance was due to indirect effects via tumor-
resident inhibitory or regulatory cells, the tumors would
become sensitive to PD-L1 blockade after re-implantation
and re-establishment of the tumor. Strikingly, mice
injected with osteosarcoma cells from α-PD-L1 mAb
treated mice and treated with additional α-PD-L1 mAb
showed no difference in survival compared to mock
treated mice (Figure 2C), suggesting that K7M2 cells were
directly inhibiting TILs by alternative pathways. An
Figure 2 Naïve mice injected with in vivo treated α-PD-L1 mAb K7M2 cells are non-responsive to α-PD-L1 treatment, suggesting resistance to α-PD-L1
treatment. Naïve Balb/cJ mice were injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma, with decreased PD-L1 expression, (B) black
histogram is PD-L1 expression prior to reimplantation in comparison to mock treated mice in white, and treated with α-PD-L1 mAb or mock (A). No
significant difference was seen between survival in treated (n = 10) and untreated (n = 10) mice injected with treated metastatic osteosarcoma (C).
PD-L1 expression on metastatic osteosarcoma from mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma compared to control
K7M2 injected mice was significantly decreased, p = 0.0026 (D). At time of necropsy, PD-1 + CTLA-4+, and LAG3+ CD8+ expression was evaluated
using Flow Jo. PD-1 + CD8+ expression was significantly different in mice injected with in vivo α-PD-L1 mAb treated metastatic osteosarcoma
compared to control K7M2 injected mice, p = 0.0017 (E). CTLA-4 + CD8+ expression was significantly different in in vivo α-PD-L1 mAb treated
metastatic osteosarcoma injected mice compared to control, p = 0.0231 (F). LAG3 + CD8+ expression was not significantly different between
these two groups (G).
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be altering the microenvironment towards a T cell sup-
pressive state, however increases in CD80/86 expression
on the tumor cells after PD-L1 treatment suggest direct
K7M2 TIL inhibition. Tumor cells from α-PD-L1 mAb
treated mice appeared to have overall slower growth kinet-
ics in vitro, compared to the parental tumor cells, result-
ing in an overall longer mean survival of ~50 days versus
only ~25 days after reimplantation of tumors from un-
treated mice, which is to be expected as PD-L1 has been
shown to speed up tumor cell growth kinetics and provide
anti-apoptotic signals [19,20] (Additional file 1: Figure S1).Tumor cells from α-PD-L1 mAb treated mice retained
low expression levels of PD-L1, compared to tumor cells
from untreated mice, whether or not additional α-PD-
L1 mAb was administered (Figure 2D) and CD8+ TILs
isolated from PD-L1 mAb resistant tumors continued
to exhibit decreased expression of PD-1 but elevated
expression of CTLA-4, while LAG3 expression remained
unchanged (Figure 2E-G). Taken together,these data sup-
port the idea that immunoselection of K7M2 metastatic
osteosarcoma cells that eventually cause lethal disease in
α-PD-L1 mAb treated mice evokes an adaptive resistance
mechanism in the microenvironment, and instead the
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ligation as an alternative pathway to escape immune
destruction.
Combination of PD-L1 mAb blockade with CTLA-4 mAb
blockade can result in complete control of metastatic
osteosarcoma tumors in a subset of mice
Due to the increased CTLA-4 expression observed on
TILs after selection of α-PD-L1 resistant tumors, and
increased CD80/86 expression on remaining tumor cells,
we hypothesized that blockade of both CTLA-4 and
PD-L1 might lead to better tumor control. Combination
of α-CTLA-4 and α-PD-L1 mAb treatment resulted in
complete control of metastatic osteosarcoma tumors
with long-term disease-free survival in roughly 60% of
α-CTLA-4 + α-PD-L1 mAb treated mice. This was in
comparison to 0% long-term survival of mice treated
with α-PD-L1 alone (p = 0.0177, Figure 3). Moreover, the
combination of these antibody blockade strategies ap-
peared to have a synergistic effect as α-CTLA-4 mAb
treatment alone showed no benefit in slowing the progres-
sion of metastatic osteosarcoma compared to untreated
mice. Additionally, tumor-specific TIL function is en-
hanced at day 25 in dual treated mice in comparison
to CTLA4 mAb alone, PD-L1 mAb alone, or mock
treated mice (Additional file 2: Figure S2).
Dual PD-L1/CTLA-4 treatment and control of metastatic
osteosarcoma leads to protective immunity against future
tumor inoculation
In order to determine if eradication of tumors in com-
bination α-CTLA-4 and α-PD-L1 mAb treated mice
resulted in sterilizing anti-tumor immunity, we next
evaluated if the α-CTLA-4/α-PD-L1 mAb treated miceFigure 3 Dual α-CTLA-4/α-PD-L1 mAb treatment can completely
eradicate metastatic osteosarcoma. Survival of combinational treatment
of implantable metastatic osteosarcoma with α-CTLA-4 and α-PD-L1
mAb was significantly higher than α-PD-L1 mAb treatment alone,
p = 0.0177. Additionally, survival of combination treatment α-CTLA-4/
α-PD-L1 mAb compared to α-CTLA-4 mAb treatment alone was
significantly different with a p value of p < 0.0001. α-CTLA-4 mAb alone
was not significantly different than mock treated mice. N = 10 for all
treatment groups.were protected against subsequent tumor inoculation.
Mice previously treated with α-CTLA-4 and α-PD-L1
mAb and that had previously controlled metastatic
osteosarcoma were challenged with 106 K7M2 cells at
100 days post-initial inoculation, a time when neither
therapeutic antibody should be present in these mice.
Mice that had controlled metastatic osteosarcoma were
selected via no detectable tumors (4 of surviving mice at
day 100 were euthanized, Additional file 3: Figure S3),
and no physical signs of disease at day 100. Strikingly, α-
CTLA-4/α-PD-L1 mAb treated mice that had controlled
initial K7M2 tumors, were completely immune to chal-
lenge with additional K7M2 cells, and remained tumor
free for an additional 80 days when they were euthanized
to evaluate immune memory (Figure 4A). At the time of
necropsy (180 days post initial tumor inoculation), these
tumor–immune mice also had no visible pulmonary
metastases (Additional file 3: Figure S3).
We next asked whether immunity to metastatic osteo-
sarcoma in combination α-CTLA-4/α-PD-L1 mAb
treated mice that controlled initial K7M2 tumors corre-
lated with retention or improved T cell function. Per-
fused lung tissue from healthy mice had few CD8 cells
present. In our previously published work, mock-treated
mice implanted with K7M2 cells had many more TILs,
but these were largely unresponsive to antigen-
stimulation with 86.07 ± 0.8253% of TILs expressing PD-
1 [6]. In contrast, in dual treated α-CTLA-4/α-PD-L1
mAb mice a large number of TILs were also observed in
α-CTLA-4/α-PD-L1 mAb treated mice. However the
vast majority (86.63 ± 6.661%) of the CD8 cells present
in the lungs of combination treated mice were able to
produce both IFNy and TNF in response to stimulation
with parental K7M2 cells in vitro (Figure 4C). This dif-
ference in function between treated and control mice
correlated with a central memory phenotype (CD62L +
CCR7+) (Figure 4B) as 85% of TILs from α-CTLA-4/α-
PD-L1 mAb treated mice were CCR7 + CD62L+ while
most cells from mock-treated mice were low for these
surface markers. Thus, the presence of high numbers of
central-memory phenotype and cytokine positive CD8 T
cells in the lung tissue from dual α-CTLA-4/α-PD-L1
mAb treated mice likely mediate protective immunity to
further K7M2 re-exposure.
In order to directly test whether the central-memory
phenotype CCR7 + CD62L + CD8+ TILs in tumor-
immune mice mediated resistance to subsequent tumor
inoculation, we depleted CD8 T cells at day 80 after pri-
mary tumor control in α-CTLA-4/α-PD-L1 mAb treated
mice with 2.43 hybidoma purified antibodies, followed by
re-challenge with additional K7M2 tumor cells. All mice
that were CD8 depleted prior to K7M2 re-challenge
succumbed to metastatic osteosarcoma, with a median
survival of ~40 days. This was in comparison to control
Figure 4 Dual α-CTLA-4/α-PD-L1 mAb treatment can elicit protective immunity towards metastatic osteosarcoma. To evaluate protective immune
responses to tumor, cured α-CTLA-4/α-PD-L1 mAb mice (n = 12) were challenged with 106 K7M2 cells at day 100. Cured α-CTLA-4/α-PD-L1 mAb
treated mice cleared disease and significantly survived longer than age-matched control mice, p = 0.0049 (A). Lung tissue was evaluated for
the presence of memory CD8 cells, and approximately 87% of the tumor-reactive memory T cells were CCR7 + CD62L+ (B). These CCR7 + CD62L +
CD8+ cells were specific towards K7M2 cells used to generate the tumor, and able to produce IFNy and TNF in response to re-exposure,
p=0.002 (C). To evaluate if protective immune responses to tumor were in fact due to memory CD8 T cells. Cured α-CTLA-4/α-PD-L1 mice
(n = 6) were depleted of CD8 T cells at day 80, and challenged with 106 K7M2 cells after depletion. Mice depleted of CD8 T cells prior to
challenge all succumbed to metastatic osteosarcoma in the lung tissue, in comparison to 100% survival (n = 6) in cured immune competent
mice challenged. A log-rank test gives a p = 0.0177 (D).
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that were re-challenged with K7M2 cells without CD8
depletion and showed no evidence of lung metastases or
disease (Figure 4D, Additional file 3: Figure S3).
Combination of PD-L1 mAb blockade with chemotherapy
shows no improvement in control of metastatic
osteosarcoma tumors
We next tested whether chemotherapy can enhance the
curative potential of PD-L1 blockade during metastatic
osteosarcoma progression in the K7M2 model, primarily
to test if the current standard of care in combination
with PD-L1 mAb can also elicit synergistic protection
versus anti-tumor effects. We hypothesized that combin-
ation with α-PD-L1 mAb blockade may result in in-
creased presentation of tumor antigens to T cells andhigher magnitude responses that may, therefore, avoid
the observed escape of tumors from this treatment, as
well as slow the overall growth of tumors to facilitate
immune control. CD4 and CD8 T cells are resistant to
doxorubicin treatment with similar stimulation between
mock and doxorubicin treated mice, however CD4 T
cells can exhibit enhanced proliferation due to increased
expression of CD40 ligand and 4-1BB when treated with
doxorubicin both in vitro and in vivo [21]. While doxo-
rubicin chemotherapy alone was effective in treating
metastatic osteosarcoma, p-value = 0.0048, we observed
no additional improvement in the survival of mice
treated with doxorubicin + α-PD-L1 mAb compared to
α-PD-L1 mAb treatment alone (Figure 5). Additionally,
we see similar trends in decreases in PD-1 and increases
in CTLA4 expression on CD8 T cells, and decreases in
Figure 5 α-PD-L1 mAb treatment coupled with doxorubicin
treatment does not enhance survival over α-PD-L1 mAb treatment
alone. Survival of combinational treatment of metastatic osteosarcoma
with doxorubicin and α-PD-L1 mAb was significantly higher than
chemotherapy treated alone group, p = 0.0026, although no significant
difference in survival was seen between combinational α-PD-L1 mAb
and doxorubicin treatment and α-PD-L1 mAb alone. N = 10 for all
treatment groups.
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treatment regardless of doxorubicin treatment (Additional
file 4: Figure S4). Thus, combination of chemotherapy
with immunotherapy approaches do not appear to have
additional beneficial effects on tumor control and mice
eventually succumb to disease similar to progression
during α-PD-L1 mAb treatment alone.
Discussion and conclusions
The prognosis for patients with metastatic osteosarcoma
remains dismal, in part, due to tumor resistance to con-
ventional chemotherapy or radiation treatments. We have
recently shown that α-PD-L1 blockade can improve sur-
vival and slow metastatic osteosarcoma progression by
partially restoring T cell function towards this tumor.
However, mice receiving immunotherapy with α-PD-L1
mAb eventually succumb to pulmonary metastatic dis-
ease. Here we show that metastatic osteosarcoma tumors
from mice treated with α-PD-L1 mAb down-regulate ex-
pression of PD-L1, and become resistant to further block-
ade treatment. Tumor resistance to this immunotherapy
appeared to be direct inhibition of TILs via ligation of
other inhibitory receptors, and correlated with an increase
in the expression of CTLA-4 on TILs. Combination
blockade with α-CTLA-4 and α-PD-L1 mAb resulted in
complete control of metastatic osteosarcoma and steriliz-
ing immunity to further tumors. This effect appeared to
be synergistic as α-CTLA-4 blockade alone had no impact
on tumor control, and α-PD-L1 blockade coupled with
the chemotherapy to slow tumor growth had no impact
on survival over α-PD-L1 blockade alone. Higher doses of
this CTLA4 mAb clone may be needed to elicit significantsurvival benefits in CTLA4 mAb treated mice alone, how-
ever, at this low dose we were still able to see a synergistic
effect when coupled with PD-L1 mAb treatment. This
may be of some advantage when treating pediatric pa-
tients, as high dose CTLA4 mAb treatment can lead to
significant secondary side effects. Thus, combinational
α-PD-L1/α-CTLA-4 blockade is an attractive combin-
ational therapy to use in humans to enhance T cell me-
diated rejection of metastatic osteosarcoma with the
ultimate goal of improving patient prognoses while
avoiding tumor escape.
This paper, to our knowledge, provides the first direct
evidence of immune escape by metastatic osteosarcoma
in response to α-PD-L1 blockade immunotherapy.
Blockade treatment reinvigorates T cell function, which
can ultimately drive immune-mediated tumor cell selec-
tion if complete eradication does not occur. Accumulat-
ing evidence suggests that although the immune system
identifies and eliminates pre-cancerous and cancerous
cells, tumors still develop in immune competent individ-
uals due to ineffective elimination, resulting in an equi-
librium phase of tumor development [22-25]. During
such an equilibrium phase, selective pressure by the im-
mune system on the tumor, with genomic instability of
the tumor cells, leads to additional heterogeneity, with
the potential for shifts in antigen presentation, reduction
of costimulatory proteins, or increases in inhibitory pro-
teins, and eventual tumor escape from immune control.
In particular, tumor cells up-regulate ligands such as PD-
L1 to exhaust T cell responses [26] and limit immune-
mediated killing [27-30]. Alternative immune checkpoint
controls (CTLA-4, PD-1, LAG-3, TIM-3) on T cells pro-
vide tumors with several options for avoiding tumor-
reactive immune responses [31-36,28]. We propose that
use of α-PD-L1 blockade alone in treating metastatic
osteosarcoma, partially reinvigorates T cell function result-
ing in slower tumor growth, but allows for tumor escape
by signaling via alternative immune inhibitory receptors
and eventual selection of resistant tumors that cause lethal
disease.
We have observed an upregulation of CTLA-4 expres-
sion on TILs, following α-PD-L1 treatment alone, as an
alternative mechanism by which tumor cells can escape
T cell responses. Certainly, clinical approaches and ex-
perimental systems using this antibody support our con-
clusions as similar results have been previously shown in
a B16 mouse model of melanoma, in which a two-fold
increase in the percentage of CTLA-4 expressing cells
after treatment with anti-PD-1 mAb was observed [8]. A
similar effect has also been observed in patients treated
with PD-1 blockade, in which increased CTLA-4 expres-
sion on TILs has been noted (personal communication
between J. Weber and M. Sznol [37]. Thus, it is likely
that this is a common mechanism by which tumor cells
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pathways in T cells leading to disease progression.
The dual α-CTLA-4/α-PD-L1 treatment in our meta-
static osteosarcoma mouse model appears to be syner-
gistic, as we observed no benefit after provision of
α-CTLA-4 mAb alone. These synergistic survival ef-
fects in mice treated with α-CTLA-4/α-PD-L1 mAb
may be mediated by TILs promoting tumor clearance
via blockade of non-overlapping pathways, which may
lead to greater restoration of T cell function, or sequen-
tial blockade of these pathways resulting from the dy-
namic expression of PD-1 and CTLA-4 during T cell
responses. Overall, greater TIL function after stimula-
tion with K7M2 cells is seen in dual blockade treated
mice at day 25 post treatment, in comparison to PD-L1
mAb alone, CTLA4 mAb alone, or mock treatment
(Additional file 2: Figure S2). Our data suggests that
CTLA-4 is upregulated on CD8+ TILs only after α-PD-L1
blockade, favoring the latter mechanism. The inhibitory
pathways of PD-1 and CTLA-4 appear to be non-
redundant with distinct mechanisms in maintenance of
peripheral tolerance, making the combination of the two
of particular interest in conferring synergistic tumor
effects mediated by CD8+ TILs [38].
An alternative explanation for the observed synergy
during combinational α-CTLA-4/α-PD-L1 blockade of
metastatic osteosarcoma is that tumor-resident regula-
tory or suppressor cells may be limiting the function of
TILs, and each antibody may be targeting pathways in
different cell types. Certainly, multiple studies have
shown that CTLA-4 blockade can deplete tissue-resident
regulatory T cells, and this in turn may indirectly affect
CD8+ TIL function, conferring control by alleviating im-
mune suppression at the tumor site [38,8]. However, the
CTLA4 mAb clone UC10-4F10-11, and dose used, sug-
gest that this is not decreased regulatory T cell mediated
effects on function. Alternatively, α-PD-L1 blockade may
alter the tumor microenvironment, in a manner favoring
T cell suppression by pathways other than PD-1, and
therefore this may not be direct K7M2 cell inhibition
leading to resistance. However, our results showing con-
tinued PD-L1 mAb resistance after re-establishment of
tumors in naïve mice suggest that such accessory cells
are likely not the primary mechanism by which TILs are
limited in their ability to mediate tumor killing. Rather,
we propose that K7M2 cells are directly inhibiting TILs
leading to T cell exhaustion, and that combination α-
CTLA-4/α-PD-L1 blockade is preventing or reversing
this process, as heightened CD80/CD86 expression is seen
on the tumor cells post α-PD-L1 blockade, mirroring
the increased CTLA4 expression on the tumor-reactive
TILs following treatment.
The Children’s Oncology Group (COG) has recently
launched a Phase I/II trial in pediatric patients withrelapsed/refractory solid tumors of nivolumab (anti-PD1
inhibitor) either alone or in combination with ipilimu-
mab (anti-CTLA-4 antibody). In the phase II portion of
the trial, osteosarcoma will be one of the expansion co-
horts to assess efficacy of these agents. Based on the re-
sults from this paper, combinational immunotherapy
coupling α-CTLA-4 and α-PD-L1 mAb treatment may
have the best chance of increasing survival in metastatic
osteosarcoma patients. One of the major challenges of
immune therapies in pediatric patients is the significant
toxicity profile of these agents seen in all types of pa-
tients, and it would be imperative to find the most toler-
able yet effective combination regimen for these agents
in pediatric patients [39]. The National Cancer Institute
recently approved a Phase I study of Ipilimumab in chil-
dren and adolescents with treatment-resistant cancers,
however no information has been published regarding
this phase I trial (NCT01445379). The COG trial would
be instrumental in providing the safety and dosing data
for pediatric patients. Results of our study and other
similar studies in preclinical models have generated a
tremendous amount of excitement regarding the huge
potential for immunotherapy of cancer and will provide
further incentive for the rational development of more
efficacious and safer targets to improve resistance to
metastatic tumors.
Methods
Antibodies and cell lines
Fluorochrome-conjugated anti-mouse monoclonal anti-
bodies (Abs) specific for CD8α, CD274, CD279, CTLA-
4, CD80, and CD86 were purchased from eBiosciences
(San Diego, CA). The anti-PD-L1 monoclonal antibody
(clone 10F.9G2) used for in vivo blockade experiments
was purchased from BioXCell (West Lebanon, NH). The
anti-CTLA-4 monoclonal antibody was purified from
the UC10-4F10-11 hybridoma, (ATCC, Manassas, VA).
K7M2 osteosarcoma cells were purchased from ATCC,
and screened by IDEXX Laboratories (Columbus, MO).
Mice and generation of tumors
3–4 week-old Balb/cJ mice were purchased from the
Jackson Laboratories (Bar Harbor, ME) and maintained
under specific pathogen-free conditions in Arizona State
University Biodesign Institute animal facilities. All exper-
iments were approved by the Arizona State University
Institutional Animal Care and Use Committee, and con-
ducted under appropriate supervision. To establish
metastatic osteosarcoma tumors in mice, 106 K7M2 cells
were injected via the lateral tail vein in 100 μL of Hanks
Balanced Salt Solution. Both weight loss and a clinical
scoring system were used to monitor for the develop-
ment of metastatic lung disease, with a mean time to
diagnosis of 24 days from injection of cells. Mice were
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appearance, respiration, ambulation, and for the occur-
rence of tremors/convulsions. Mice were euthanized for
analysis by CO2 asphyxiation when weight loss was >10%
and/or physical symptoms (a cumulative score > 6 or a
score of 3 in any individual category) were observed.
For significance, all treatment groups consisted of n = 10
or more.Lung preparation
Mice with metastatic pulmonary disease were anesthe-
tized with a mouse ketamine cocktail administered IP
using the dose of 42mg/kg ketamine, 4.8 mg/kg xylazine,
and 0.6 mg/kg acepromazine followed by lung perfusion
with ice-cold PBS to remove peripheral blood mono-
nuclear cells (PBMC). Mice were then euthanized as de-
scribed above. Lungs were collected in RPMI media and
Metastatic osteosarcoma-infiltrating cells were isolated
from collagenase-treated lung tissue by centrifugation
over a 30/90% Percoll gradient (Sigma-Aldrich, St. Louis,
MO) and collection of interface cells before antibody
staining of cell populations on an LSRFortessa II flow
cytometer (BD Biosciences, San Jose, CA) [40]. Flow cy-
tometry data were analyzed with FlowJo8.8 (Tree Star
Inc., Ashalnd, OR) and graphs generated with Prism5
software (GraphPad Software, La Jolla, CA). Statistical
significance reported * p < 0.05, ** p < 0.01, *** p < 0.001,
and **** p < 0.0001.Intracellular cytokine staining
Lymphocytes were cultured alone or stimulated with
K7M2 cells. GolgiStop (BD Biosciences) was added at 1
hour to inhibit export of cytokines and after a further 5
hours of incubation, cells were stained for extracellular
proteins [41]. Permeabilization and intracellular stain-
ing for cytokines was done according to manufacturer’s
instructions using the Cytofix/Cytoperm kit (BD/
Pharmingen).Cytotoxicity ELISA
Lymphocytes were isolated from lung tissue, and cultured
alone or with K7M2 cells. LDH Elisa was performed
using CytoTox 96 Non-Radioactive Cytotoxicity Assay
(Promega, Madison, WI) and absorbance was recorded
at 490nm.In vivo PD-L1 antibody blockade
Mice inoculated with K7M2 cells as described above
were administered 200 μg PD-L1 antibody (10F.9G2) in
PBS or mock PBS control intraperitoneally every three
days, starting one day after tumor inoculation [42].In vivo CTLA-4 antibody blockade
Supernatant from UC10-4F10-11 hybridoma cells [43]
was precipitated in saturated ammonium sulfate to 45%
(v/v) overnight at 4°C and dialyzed against PBS for 24
hrs. The concentration of dialyzed antibody was deter-
mined by UV spectrophotometer analysis using a Nano-
drop (Thermo Scientific). Mice inoculated with K7M2
cells as described above were administered 100 μg
CTLA-4 antibody in PBS or mock PBS control intraperi-
toneally every three days, starting one day after tumor
inoculation [44,45].
In vivo doxorubicin treatment
Doxorubicin hydrochloride (Sigma-Aldrich), was injected
at 2mg/kg into the lateral tail vein of K7M2 inoculated
mice at +7 days from tumor cell injection [46].
Reimplantation of PD-L1 treated metastatic osteosarcoma
Mice inoculated with K7M2 cells were euthanized after
presenteding with clinical symptoms. Metastatic osteo-
sarcoma lung tissue was processed as described above,
without Percoll gradient separation. After cell counting
and staining to determine the percentage of osteosar-
coma cells, 106 tumor cells were re-implanted into naïve
3–4 week old Balb/cJ mice.
PD-L1 knock-down in K7M2 cells
293FT cells were purchased from ATCC, and were
plated at a low confluency on 10cm dishes. The ViraPower
Lentiviral Expression System, purchased from Life
Technologies (Carlsbad, CA), was incubated with the
CD274-set siRNA/shRNA/RNAi Lentivector, purchased
from Applied Biological Materials (Richmond, BC), to
transfect 293FT cells and incubated overnight at 37
degrees prior to harvesting the virus. Virus was used to
transduce K7M2 cells by incubating for 48 hrs at 37
degrees. Once the transduced K7M2 cells were conflu-
ent, cells were stained with anti-PD-L1 and Propidium
Iodide followed by analysis of cell populations on an
LSRFortessa flow cytometer. Flow cytometry data were
analyzed with FlowJo8.8 and ModFitLT, and graphs
generated with Prism5 software. Paired T test was used
to generate statistical significance.
Additional files
Additional file 1: Figure S1. PD-L1 expression enhances K7M2 cell
proliferation and promotes anti-apoptotic signals. Flow cytometry plots
gating on K7M2 PD-L1 positive cells versus K7M2 PD-L1 negative cells from
flask treated with lentiviral vector containing PD-L1 shRNA, propidium
iodide stain reveals number of cells in G1, G2, and S phase (A). Graphical
representation of the different percentage of cells in G1 versus G2 and S
between K7M2 PD-L1 positive cells versus K7M2 PD-L1 negative cells. PD-L1
expression significantly decreased the number of cells in G1, p < 0.01. PD-L1
expression significantly increased the number of cells in G2 and S, p < 0.01
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decreases amount of apoptosis significantly, p < 0.01 (C).
Additional file 2: Figure S2. Dual blockade treated tumor-specific TILs
are more functional at day 25 in comparison of PD-L1 mAb alone, CTLA4
mAb alone, or mock treated mice. TILs isolated from mice of varying
treatments were cultured alone, or with K7M2 cells used to generate the
tumor. IFNy, TNF, and IL-2 function was evaluated (A, B, and C). Mice treated
with CTLA4 and PD-L1 mAbs had significantly higher IFNy production in
comparison to mice treated with either PD-L1 mAb alone, CTLA4 mAb
alone, or mock treated, p < 0.0001 (A). Mice treated with CTLA4 and PD-L1
mAbs had significantly higher TNF production in comparison to mice
treated with either PD-L1 mAb alone p < 0.05, CTLA4 mAb alone p < 0.01,
or mock treated p < 0.001 (B). Mice treated with CTLA4 and PD-L1 mAbs
had significantly higher IL-2 production in comparison to mice treated with
either PD-L1 mAb alone p < 0.01, CTLA4 alone p < 0.001, or mock treated
mice p < 0.001 (C). LDH ELISA confirming increased TIL function in dual
treated mice with a significant increase in % cytotoxicity between PD-L1
mAb alone p < 0.01, CTLA4 alone p < 0.0001, or mock treated p < 0.0001 (D).
Additional file 3: Figure S3. Pictures of mouse lung tissue with varying
treatments. Healthy lung tissue (A). K7M2 metastatic disease with no
treatment (B). K7M2 metastatic disease at time of death in PD-L1 mAb
blockade treated mice (C). Mice injected with K7M2 cells and treated with
both PD-L1 and CTLA4 mAbs, and osteosarcoma controlled. No physical
signs of disease, euthanized at day 100 (D). Osteosarcoma immune mice,
challenged at day 100, euthanized with no physical signs of disease at
day 180 (E).
Additional file 4: Figure S4. TIL phenotype in dual treated α-PD-L1
mAb and doxorubicin treatment. N = 10 for all treatment groups. At time
of necropsy, PD-1+ and CTLA-4+ CD8+ expression was evaluated using
Flow Jo. PD-1 + CD8+ expression was significantly different in dual
doxorubicin and PD-L1 mAb treatment versus doxorubicin alone mice,
p < 0.001 (A). CTLA-4 + CD8+ expression was significantly different in
PD-L1 mAb treatment versus doxorubicin alone mice, p < 0.01 (B). PD-L1
xpression was significantly decreased in dual doxorubicin and PD-L1 mAb
treatment versus doxorubicin alone mice, p < 0.01.
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